A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
\"The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic malignancies.
Epistemonikos ID: 529ace15f9f8c85e157cbbff972e7a21a766b32b
First added on: May 22, 2024